undamentalytics Newsletter
Sign in

Alaunos Therapeutics, Inc. revenue

Alaunos Therapeutics, Inc.'s revenue was $5,000 in fiscal 2025, down 50.0% on the year before. Since fiscal 2011 ($667,000) it has grown at a compound -38.7% a year. Over the last twelve months it was $3,000.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122016Dec 20162017Dec 20172018Dec 20182020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1171600030000
Growth on the year before—+19.9%+757.6%+131.7%−99.1%−100.0%—+634.2%−99.8%+100.0%−50.0%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Alaunos Therapeutics, Inc. $3,000 -50.0% -89.9%
Creative Medical Technology Holdings, Inc. $3,000 -50.0% -65.6%
Lyell Immunopharma, Inc. $27,000 -55.0% -91.8%
AIM Immunotech Inc. $95,000 -21.5% -17.3%
Ibio, Inc. $100,000 -75.0% -62.4%
Lisata Therapeutics, Inc. $100,000 -90.7% —

Compare with peers

Head to head: CELZ vs TCRTLYEL vs TCRTAIM vs TCRT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Alaunos Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Alaunos Therapeutics, Inc.